{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T11:49:00Z","timestamp":1759837740108},"reference-count":65,"publisher":"Wiley","issue":"2-3","license":[{"start":{"date-parts":[[2006,11,14]],"date-time":"2006-11-14T00:00:00Z","timestamp":1163462400000},"content-version":"vor","delay-in-days":6892,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J of Clinical Apheresis"],"published-print":{"date-parts":[[1988,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Intravenous immune globulin (IVIG) is indicated for IgG replacement in antibody deficiency syndromes and as immune\u2010regulatory therapy in some autoimmune diseases. Two case histories, illustrate both aspects of IVIG therapy.<\/jats:p><jats:p>1. Patient 1 is a 24\u2010year\u2010old male with agammaglobulinemia. He was successively treated with monthly IMIG, paternal plasma, and then over the last 5 years, IVIG. On IgG doses of 250 mg\/kg q\/4 weeks, IgG trough levels remained below 200 mg IgG\/dl. IgG half\u2010life was reduced. Although asymptomatic for prolonged periods of time, he eventually developed clinically evident inflammatory bowel disease. Optimal IVIG replacement therapy requires normal IgG half\u2010life and adequate IgG bough levels.<\/jats:p><jats:p>2. Patient 2 is a 12\u2010year\u2010old girl with autoimmune neutropenia, recurrent skin infections, and items unresponsive to antibiotics and to steroid therapy. IVIG at a dose of 3,000 mg\/IgG\/kg over 3 days significantly increased her neutrophil count. Subsequently, she has required 1,000 mg\/kg of IVIG q\/4 weeks for maintenance. Antineutrophil autoantibodies have persisted. There is synergism of IVIG \u2010with high doses of corticosteroids. The mechanism of action of IVIG seems to involve a blockage of the RES system.<\/jats:p><jats:p>IVIG therapy is safe even at high doses for most patients. However, anaphylactic reactions have been observed in IgA\u2010deficiem patients with IgE anti\u2010IgA antibodies. The full spectrum of therapeutic applications of IVIG is still being explored, for some patients self\u2010infusion of IVIG at home is an appealing treatment alternative.<\/jats:p>","DOI":"10.1002\/jca.2920040212","type":"journal-article","created":{"date-parts":[[2007,2,21]],"date-time":"2007-02-21T15:07:47Z","timestamp":1172070467000},"page":"97-103","source":"Crossref","is-referenced-by-count":9,"title":["Clinical uses of intravenous immune globulin: Immunoglobulin replacement therapy and treatment of autoimmune cytopenias"],"prefix":"10.1002","volume":"4","author":[{"given":"Ricardo U.","family":"Sorensen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melissa O.","family":"Kallick","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2006,11,14]]},"reference":[{"key":"e_1_2_1_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/0090-1229(84)90185-5"},{"key":"e_1_2_1_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(84)90325-5"},{"key":"e_1_2_1_4_2","first-page":"141","article-title":"Gammaglobulin replacement","volume":"5","author":"Buckley RH","year":"1985","journal-title":"Clin Immunol Allergy"},{"key":"e_1_2_1_5_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1423-0410.1982.tb00014.x"},{"issue":"3","key":"e_1_2_1_6_2","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/0002-9343(84)90322-X","article-title":"Prolonged interval high\u2010dose intravenous immunoglobulin in patients with primary immunodeficiency states","volume":"76","author":"Montanaro A","year":"1984","journal-title":"Am J Med"},{"key":"e_1_2_1_7_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.146.2.377"},{"key":"e_1_2_1_8_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1423-0410.1985.tb01138.x"},{"key":"e_1_2_1_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(85)90006-3"},{"key":"e_1_2_1_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(86)92826-6"},{"key":"e_1_2_1_11_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2362.1973.tb00357.x"},{"key":"e_1_2_1_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(84)90334-6"},{"key":"e_1_2_1_13_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/153.3.478"},{"key":"e_1_2_1_14_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-97-1-11"},{"key":"e_1_2_1_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(84)90331-0"},{"key":"e_1_2_1_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(84)90332-2"},{"key":"e_1_2_1_17_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198308253090803"},{"key":"e_1_2_1_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-3476(85)80505-9"},{"key":"e_1_2_1_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-3476(85)80320-6"},{"key":"e_1_2_1_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(82)90923-8"},{"key":"e_1_2_1_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(84)90344-9"},{"key":"e_1_2_1_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(84)90328-0"},{"key":"e_1_2_1_23_2","doi-asserted-by":"publisher","DOI":"10.1203\/00006450-198609000-00019"},{"key":"e_1_2_1_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-3476(87)80514-0"},{"key":"e_1_2_1_25_2","doi-asserted-by":"publisher","DOI":"10.1097\/00006454-198607000-00002"},{"key":"e_1_2_1_26_2","doi-asserted-by":"publisher","DOI":"10.1097\/00006454-198607000-00003"},{"key":"e_1_2_1_27_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198211113072001"},{"key":"e_1_2_1_28_2","doi-asserted-by":"publisher","DOI":"10.1097\/00006454-198605010-00004"},{"key":"e_1_2_1_29_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00445799"},{"key":"e_1_2_1_30_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198105213042107"},{"key":"e_1_2_1_31_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198502073120605"},{"key":"e_1_2_1_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(84)91504-6"},{"key":"e_1_2_1_33_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198608073150601"},{"key":"e_1_2_1_34_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(86)90115-7"},{"key":"e_1_2_1_35_2","doi-asserted-by":"publisher","DOI":"10.1038\/323814a0"},{"key":"e_1_2_1_36_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(81)92400-4"},{"key":"e_1_2_1_37_2","doi-asserted-by":"publisher","DOI":"10.3109\/07357908509039797"},{"key":"e_1_2_1_38_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-3476(83)80608-8"},{"key":"e_1_2_1_39_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00319966"},{"key":"e_1_2_1_40_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1423-0410.1985.tb01140.x"},{"key":"e_1_2_1_41_2","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1182\/blood.V62.2.398.398","article-title":"Reversal of neutropenia with intravenous gammaglobulin in autoimmune neutropenia of infancy","volume":"62","author":"Bussel JB","journal-title":"Blood"},{"key":"e_1_2_1_42_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198207223070420"},{"key":"e_1_2_1_43_2","first-page":"1512","article-title":"Hautes doses d'immunoglobulines par voie intravenineuse pour le traitement des neutropenies auto\u2010immunes","volume":"115","author":"Beris PH","year":"1985","journal-title":"Schweiz Med Wochenschr"},{"key":"e_1_2_1_44_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-3476(86)80690-4"},{"key":"e_1_2_1_45_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00451950"},{"key":"e_1_2_1_46_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00320269"},{"key":"e_1_2_1_47_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-3476(86)80691-6"},{"key":"e_1_2_1_48_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI109915"},{"key":"e_1_2_1_49_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00320302"},{"key":"e_1_2_1_50_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1423-0410.1985.tb01143.x"},{"key":"e_1_2_1_51_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-3476(86)80772-7"},{"key":"e_1_2_1_52_2","doi-asserted-by":"crossref","unstructured":"SultanY MaisonneuveP KazatchkineMD NydeggerUE: Anti\u2010idiotypic suppression of autoantibodies to factor VII (antihaemo\u2010philic factor) by high\u2010dose intravenous gammaglobulin.Lancet766\u2013768 1984.","DOI":"10.1016\/S0140-6736(84)90701-3"},{"key":"e_1_2_1_53_2","first-page":"6273","article-title":"Characterization of various immunoglobulin preparations for intravenous application. I. Protein composition and antibody content","volume":"42","author":"Rofner J","year":"1982","journal-title":"Vox Sang"},{"key":"e_1_2_1_54_2","first-page":"266","article-title":"Subclass composition of intravenous IgG preparations","volume":"19","author":"Skavril F","year":"1986","journal-title":"Monogr Allergy"},{"key":"e_1_2_1_55_2","doi-asserted-by":"publisher","DOI":"10.1093\/clinids\/8.Supplement_4.S391"},{"key":"e_1_2_1_56_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1423-0410.1962.tb03240.x"},{"key":"e_1_2_1_57_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(84)90324-3"},{"key":"e_1_2_1_58_2","first-page":"223","volume-title":"Immunotherapy\u2014A Guide to Immunoglobulin Prophylaxis and Therapy","author":"Barandun S","year":"1981"},{"key":"e_1_2_1_59_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(86)90296-2"},{"key":"e_1_2_1_60_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198602273140907"},{"key":"e_1_2_1_61_2","doi-asserted-by":"publisher","DOI":"10.1016\/0090-1229(77)90116-7"},{"key":"e_1_2_1_62_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(84)91506-X"},{"key":"e_1_2_1_63_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(85)91430-8"},{"key":"e_1_2_1_64_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198602063140614"},{"key":"e_1_2_1_65_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1537-2995.1986.26286152919.x"},{"key":"e_1_2_1_66_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0091-6749(87)80270-1"}],"container-title":["Journal of Clinical Apheresis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fjca.2920040212","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jca.2920040212","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,31]],"date-time":"2023-08-31T10:04:40Z","timestamp":1693476280000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/jca.2920040212"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1988,1]]},"references-count":65,"journal-issue":{"issue":"2-3","published-print":{"date-parts":[[1988,1]]}},"alternative-id":["10.1002\/jca.2920040212"],"URL":"https:\/\/doi.org\/10.1002\/jca.2920040212","archive":["Portico"],"relation":{},"ISSN":["0733-2459","1098-1101"],"issn-type":[{"value":"0733-2459","type":"print"},{"value":"1098-1101","type":"electronic"}],"subject":[],"published":{"date-parts":[[1988,1]]}}}